title: Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
abstract: Half of a century ago, physicians managing chronic lymphocytic leukemia (CLL) recognized some of its presenting features such as lymphocytosis, lymphadenopathy, and splenomegaly. Subsequently, an enhanced understanding of the disease mechanisms involved in CLL led to new, more targeted treatments. There is now a plethora of treatments available for CLL. In this review article we discuss in detail several of the novel agents that are being studied or approved for the treatment of CLL including: phosphatidylinositol 3-kinase inhibitors (idelalisib and IPI-145), Bruton tyrosine kinase inhibitors (ibrutinib), B cell lymphoma 2 inhibitors (ABT-263 and ABT-199), new anti-CD20 monoclonal antibodies (obinutuzumab), cyclin-dependent kinase inhibitors (flavopiridol and dinaciclib), immunomodulators (lenalidomide) and chimeric antigen receptor T-cell therapy.
authors.affiliation: NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY.
authors.forename: Anjali Varma
authors.initials: AV
authors.lastname: Desai
authors.affiliation: NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY.
authors.forename: Hassan
authors.initials: H
authors.lastname: El-Bakkar
authors.affiliation: NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY. Electronic address: maher.abdulhay@nyumc.org.
authors.forename: Maher
authors.initials: M
authors.lastname: Abdul-Hay
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000814:Aniline Compounds / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use; D003497:Cyclic N-Oxides; D005419:Flavonoids / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007212:Indolizines; D007546:Isoquinolines / Q000627:therapeutic use; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D011687:Purines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011726:Pyridinium Compounds / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use; D011948:Receptors, Antigen, T-Cell / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000814:Aniline Compounds; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003497:Cyclic N-Oxides; D005419:Flavonoids; D007155:Immunologic Factors; D007212:Indolizines; D007546:Isoquinolines; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D011687:Purines; D011720:Pyrazoles; D011726:Pyridinium Compounds; D011743:Pyrimidines; D052999:Quinazolinones; D011948:Receptors, Antigen, T-Cell; D013449:Sulfonamides; C551803:ibrutinib; C077990:alvocidib; C553669:dinaciclib; D013792:Thalidomide; C586691:duvelisib; D000077269:Lenalidomide; D000225:Adenine; C579720:venetoclax; C543332:obinutuzumab; C528561:navitoclax; C552946:idelalisib
keywords: B cell lymphoma 2 inhibitors; Bruton tyrosine kinase inhibitors; CDK inhibitors; Immunomodulators; PI3K inhibitors